Mizuho Raises Enliven Therapeutics Target to $45, Stock Hits 5-Year High

NEW YORK, March 27 —

Mizuho raised its price target on Enliven Therapeutics Inc. (ELVN) to $45 from $41 while maintaining an Outperform rating, driving shares to their highest level in five years.

The 10% target increase extends Mizuho's bullish stance on the clinical-stage biopharmaceutical company. Investors are waiting on clinical trial readouts for Enliven's precision oncology candidates. Shares hit five-year highs ahead of those data releases.

Enliven's stock broke through multi-year resistance even as biotech funding has tightened across the sector. The company develops drugs targeting cancer patients with specific genetic mutations. That narrow focus has drawn institutional interest in precision medicine.

Investors should watch upcoming clinical trial data and earnings reports for signs that Mizuho's thesis holds. Enrollment updates, safety profiles, and efficacy signals from ongoing studies will determine whether shares can hold above recent five-year highs.

Trading at $39.29 with a forward P/E ratio of -15.5x, Enliven carries the standard valuation of a development-stage biotech generating no revenue while advancing its pipeline. The negative earnings multiple reflects the company's pre-revenue status and the risks that come with clinical-stage drug development.

The Mizuho target implies roughly 15% upside from current levels. Analysts cite pipeline value despite execution risks. The revision may draw additional institutional coverage as the company approaches clinical readouts. Still, coordinated analyst target increases in biotech don't always tell the full story — Alumis drew similar upgrades despite a 28% earnings miss.

Not all signals point the same way. Enliven's CSO recently sold $500k in stock at these same five-year highs, a transaction worth weighing against the optimism in Mizuho's revised target.

For full analysis and real-time tracking of ELVN's fundamentals and technical indicators, visit /stock/elvn to generate a detailed Basis Report.

Basis Report does not hold positions in securities discussed. This is not investment advice.